Further findings from a Phase I trial of CAR-T in MS: patient-reported outcomes

Jeffrey Dunn, MD, Stanford University School of Medicine, Palo Alto, CA, shares insights into the patient-reported outcomes of CAR T-cell therapy in multiple sclerosis (MS) from a Phase I trial (NCT06138132). He discusses that patients were discharged after the infusion of CAR-T therapy, after which they experienced malaise. After about three months, patients reported significant improvements in fatigue levels. These findings highlight the potential clinical activity of CAR-T therapy, but Prof. Dunn emphasizes that they must be replicated and validated in larger cohorts. This interview took place at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.